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Screening is an attractive approach to preventive medicine, but it can damage health as well as improve it. In 1968, Wilson and Jungner set out 10 criteria by which new screening programmes could be assessed.' It is difficult for a programme to fulfil all the criteria but failure in just one can be the downfall of an otherwise excellent project. The Wilson and Jungner criteria have stood the test of time2 but we will suggest some minor changes and consider their relevance to paediatric practice, with special reference to a proposed screening programme for extrahepatic biliary atresia (EHBA) and other liver diseases of infancy (table 1).3 Criterion 1 -the condition must be an important public health problem 'Important' in this context cannot be judged by frequency alone. As children become healthier, rare diseases assume increasing significance. Phenylketonuria for example is rare, but the phenylketonuria programme is cost effective and fulfils screening criteria very well. Nevertheless, there are rarely sufficient data to permit a totally objective analysis and value judgments will always have to be made, taking into account the nature of the disease process, the distress and suffering caused, and the emotional impact of these on the family and society.
Criterion 2 -an effective treatment must be available This may not be an essential criterion in paediatric practice (see criterion 8).
Criterion 3 -facilities for diagnosis and treatment should be available Conditions such as EHBA should usually be managed in tertiary centres. Delays in referral for definitive investigation and treatment are sometimes due to professional failure, at primary or secondary care level, to recognise the nature of the problem4 -for instance, EHBA may be misdiagnosed as breast milk jaundice. A less forgivable cause of delay is the desire to investigate an 'interesting case' oneself. Screening programmes cannot address There is an agreed definition of EHBA and the detection of other liver diseases will be beneficial.
There is no doubt that early recognition of EHBA and other liver disorders improves prognosis.
True costs of screening for EHBA not known but are probably higher than estimated by Mowat et al.3 The need for repeated screening and continuous vigilance will need to be assessed in field trials of a screening programme. 
be important to test the benefits (and hazards) of teaching parents how to identify possible abnormality and obtain relevant professional advice.
Criterion 5 - Criterion 8 -early treatment should improve outcome Many screening programmes have been launched in the confident belief that early intervention will improve outcome. In some instances, for example in congenital sensorineural deafess, it may never be possible to determine whether this is so. In others, such as Duchenne muscular dystrophy, the outcome is not improved but parents can plan for the future and avoid the birth of a second affected child.
Why does early diagnosis of serious disease seem so important to parents even when it makes little or no difference to outcome? Parents will always speculate about what might have happened if treatment had been started earlier. Avoidable delays in diagnosis and referral feed the natural sense of anger and betrayal felt by the parents of a sick child. Parents of disabled children say that they want to know about the child's problems as soon as possible. It seems that the longer the parents' shared life with a child they believe to be normal, the more devastating is the discovery of a serious illness or disorder. If they have received good care from the first suspicion through to tertiary referral, their memories of the whole process, though still painful, will be less embittered.
Criterion 9 -cost of screening should be economically balanced The cost can be stated in terms of the total programme cost, the cost per child screened, or the cost per case detected. The true costs are usually underestimated and include test materials or reagents; written information about the condition (for example in the personal child health record); professional time spent in explaining the test and obtaining consent, performing and interpreting the test, assessing and reassuring screen failures at the specialist clinic, monitoring and auditing the programme; time to answer further questions and queries; training staff; insurance against litigation resulting from badly performed tests or failure to test the whole population. Some authorities include the parents' time and travel to hospital for investigation'4 and the cost of psychological distress associated with false positive screening tests.
Programme costs are not directly proportional to the volume and duration of work generated by the new test.'5 For example, a procedure that can be completed in one or two minutes might be absorbed into existing work routines without appreciable cost to other activity, but one that takes 10 or 15 minutes (such as obtaining and testing a urine specimen) might require either an increase in staff or reduction in some other service.
Similarly) a screening procedure for EHBA might be affordable if it could be incorporated into the first visit by the health visitor, but the cost would escalate if a separate visit were needed specifically for that purpose, for instance at 21 or 28 days.
The cost per case detected is calculated by dividing the programme cost by the number of cases actually discovered by the screening programme, not by the total number of cases in the population being screened. The benefits of screening, however, may not necessarily be realised as a direct result of the screening test itself. Some cases of a condition like EHBA will be ascertained by other means, and this number may well increase as a result ofthe raised awareness generated by a screening programme.
How much are we prepared to pay to ensure that all cases of EHBA are diagnosed by the age of 6 weeks? Screening programmes are expensive but it is important to calculate both costs and benefits appropriately. In the case of EHBA, the potential savings reflect not only the costs of liver transplantation, but also the prevention of brain damage due to intracranial bleeding associated with other forms of liver disease and, most importantly, a great deal of parental stress and grief and children's suffering. There is a recent tendency to assume that a screening programme must be cheaper than the health care costs of the condition it aims to discover. Prevention is better than cure -so it does not have to be cheaper.
Criterion 10 -case finding may need to be a continuous process Continued vigilance and repeated screening may be necessary because new cases appear continuously in the population. In this situation, however, each successive screening procedure might have a decreasing chance of detecting new cases and an increasing probability that screen failures will be false positives. Suspicion that the screening test itself is inadequate or that the standard of testing is poor is not a valid reason for repeated screening.
Would screening at more than one point in time be needed for EHBA? The age of presentation varies and some cases may not be recognisable in the first two weeks of life.16 A case could therefore be made for any screening to be deferred until 4 weeks of age, thus reducing the number of false positives yet still meeting the deadline at 6 weeks beyond which treatment is less effective.
Conclusion
In the case of EHBA and other liver diseases of infancy, we need to determine the sensitivity and specificity of the candidate screening procedures. The direct measurement of these, in a condition that occurs in each district only once every few years, would need a nationwide study and would be more expensive than can currently be justified. Less ambitious studies may help. The sensitivity could be estimated from analysis of early symptoms and signs, and their evolution, in an unselected series of cases of EHBA and other liver disorders. The specificity could be assessed by introducing the candidate screening procedures in one or two districts.
Developing a good screening test is only a small part of the challenge. Anxiety must be minimised by the provision of efficient diagnostic services, adequate information, and continuing support. In addition, a screening programme will heighten public awareness about breast milk jaundice and efforts will be needed to avoid further falls in the rate of breast feeding.
